Drugs / ABSK141
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07417189 | Mar 2026 → Dec 2028 expected | — | Abbisko Therapeutics Co, Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-04-23 | Abbisko Therapeutics Co, Ltd | Results AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches abbisko.com ↗
Preclinical studies demonstrated that ABSK131 exhibits strong synergistic activity with multiple therapies: |
| 2025-12-24 | Abbisko Therapeutics Co, Ltd | Regulatory Abbisko Therapeutics Announces IND Clearance from the NMPA for Oral Small Molecule KRAS G12D Inhibitor ABSK141 abbisko.com ↗
Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announced that the China National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for ABSK141 |
| 2025-12-02 | Abbisko Therapeutics Co, Ltd | Regulatory Abbisko Therapeutics Announces IND Clearance from the FDA for Oral Small Molecule KRAS G12D Inhibitor ABSK141 abbisko.com ↗
1 December 2025, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for ABSK141, an oral, highly potent and selective small-molecule KRAS G12D inhibitor, for the treatment of patients with advanced solid tumors harboring KRAS G12D mutations. |
| 2024-10-24 | Abbisko Therapeutics Co, Ltd | Results Abbisko presented preclinical research results of its PRMT5* MTA and oral KRASG12D programs at the 36th International Molecular Targets and Cancer Treatment Conference (EORTC-NCI-AACR) abbisko.com ↗
ABSK141 demonstrated high binding affinity and good biochemical activity to KRASG12D in vitro. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-23 | Abbisko Therapeutics Co, Ltd | AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches abbisko.com ↗ |
| 2026-03-04 | Abbisko Therapeutics Co, Ltd | Abbisko Therapeutics’ Oral Small-Molecule KRAS G12D Inhibitor ABSK141 Completed First Patient Dosing abbisko.com ↗ |
| 2025-12-24 | Abbisko Therapeutics Co, Ltd | Abbisko Therapeutics Announces IND Clearance from the NMPA for Oral Small Molecule KRAS G12D Inhibitor ABSK141 abbisko.com ↗ |
| 2025-12-02 | Abbisko Therapeutics Co, Ltd | Abbisko Therapeutics Announces IND Clearance from the FDA for Oral Small Molecule KRAS G12D Inhibitor ABSK141 abbisko.com ↗ |
| 2024-10-24 | Abbisko Therapeutics Co, Ltd | Abbisko presented preclinical research results of its PRMT5* MTA and oral KRASG12D programs at the 36th International Molecular Targets and Cancer Treatment Conference (EORTC-NCI-AACR) abbisko.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABSK141 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07417189 ↗ |
| Route | Oral | “administered orally” NCT07417189 ↗ |